^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    DLL3 expression

    i
    Other names: DLL3, Delta Like Canonical Notch Ligand 3, Drosophila Delta Homolog 3, Delta-Like Protein 3, Delta3, Delta (Drosophila)-Like 3, Delta-Like 3 (Drosophila), Delta-Like 3, SCDO1
    Entrez ID:
    10683
    Related biomarkers:
    Expression
    2years
    #AACR22 #SCLC 2 really interesting #DLL3 focused abstracts, #5305 by @LaurenByersMD group demonstrating DLL3 expression was observed in 82% of all cases, and #5550 from @QiluPharmaNews demonstrated in-vivo activity of bi-specific Ab @HemOncFellows @OncoAlert (@ADesaiMD)
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    over2years
    DLL3 expression seen in majority of #SCLC and #LCNE specimens but also seen in 12% typical carcinoid and 24% atypical carcinoid. Appealing therapeutic target with tarlatamab in development (AMG 757, BiTE). Will we see more agents for this target in #NETS? https://t.co/mYu2VBMXxu (@StephenVLiu)
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    tarlatamab (AMG 757)
    over2years
    A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. https://t.co/s4xyOylvm7 (@DavidHongMD)
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    Rova-T (rovalpituzumab tesirine)
    3years
    MERU enrolled 748 pts with ES-SCLC with no progression 3-9wks after 1L platinum-based chemotherapy. Pts were randomized 1:1 to Rova-T (0.3mg/kg q6w omitting every 3rd cycle) or placebo. Stratified by DLL3 expression, response to 1L, CNS mets, and PCI. (@StephenVLiu)
    Clinical
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    Rova-T (rovalpituzumab tesirine)
    3years
    TAHOE was a pure 2nd line #SCLC trial. Enriched population of only high DLL3 expression by IHC (75% by SP347). Allowed treated stable CNS metastases. Primary endpoint OS. 2:1 randomization to Rova-T vs standard q3w topotecan. Included stratification by platinum sensitivity. (@StephenVLiu)
    Clinical
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    topotecan • Rova-T (rovalpituzumab tesirine)